Novavax reported $2.16B in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adma Biologics ADMA:US $ 28.07M 3.5M
Agenus AGEN:US $ 159.72M 3.34M
Astrazeneca AZN:US $ 21815M 925M
AstraZeneca AZN:LN 21815M 925M
Dynavax Technologies DVAX:US $ 345.2M 121M
Genocea Biosciences GNCA:US $ 18.03M 0.65M
Geron GERN:US $ 46.88M 0.25M
GlaxoSmithKline GSK:LN 37835M 13557M
Mannkind MNKD:US $ 59.56M 6.07M
Minerva Neurosciences NERV:US $ 3.41M 0.16M
Moderna Inc MRNA:US 6.81B 2.43B
Novartis NVS:US $ 27646M 2161M
Novavax NVAX:US $ 2156.24M 104.77M
Pain Therapeutics PTIE:US $ 8.72M 1.93M
Peregrine Pharmaceuticals PPHM:US $ 75.76M 1.54M
Sarepta Therapeutics SRPT:US $ 545.57M 90.6M